BLOG
Whole Health Series:
Mental Health & Breast Care
Whole Health Series:
Guide for Fertility & Preservation
Whole Health Series:
Navigating the Stages of Healing in Survivorship
- Whole Health Series
- Who we are
- Wellness & Prevention
- Warrior
- Uncategorized
- Twitter Chats
- Triple Negative Breast Cancer
- Toolkit
- Tiger Talk Blog Series
- The Fearless Warrior Project
- Survivorship
- Stories
- Spirituality
- SABCS 2023
- SABCS
- Resources
- Reflections
- Publications
- Programs
- Press Release
- Nutrition
- Newsletter
- MY LIFE
- My Life
- Mindful Moments
- Metastatic Breast Cancer
- Metastatic Breast Cancer
- Love Your Bones
- Living with MBC
- Healthy Lifestyle
- Education
- Conquer
- Clincial Trials
- CLEART
- children
- Breast Cancer Toolkit
- Breast Cancer 101
- bone health
- Blog
- ANGEL Advocate
A Closer Look at SABCS with Kawana Rucker, Tigerlily ANGEL Advocate
Throughout SABCS week, we’ll be sharing some ideas, reflections, and opinions of patient advocates who attended. Each evening, we’ll share a little about each Tigerlily ANGEL Advocate, their story, and […]
HEALing Through Advocacy and Allyship
By: Maimah Karmo One of my favorite poets, Rumi said, “The Universe is not outside of you. Look inside yourself; everything that you want, you already are.” I take this […]
Tigerlily Foundation Releases a Powerful New Policy Brief Revealing Egregious Disparities in Screening and Diagnosis for Triple Negative Breast Cancer (TNBC)
November 3, 2021 – A newly released policy brief from the Tigerlily Foundation reveals egregious disparities in screening and diagnosis for Triple Negative Breast Cancer (TNBC) – the most aggressive form of breast cancer that disproportionately affects minority communities and is diagnosed more frequently in younger women and women of color – and offers urgently needed policy solutions to address them.
Study Sponsor: Seagen
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan. It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab deruxtecan.
Study Sponsor: Sanofi
This study looks at how safe and effective the study drug, atezolizumab, is when given with paclitaxel. To do this, they are comparing the treatment regimen with and without the study medication.
Study Sponsor: Genentech/Hoffmann-La Roche
This study looks at how safe and effective the study drug, atezolizumab, is when given with paclitaxel. To do this, they are comparing the treatment regimen with and without the study medication.
